SLDB · Solid Biosciences Inc.
$9.20
+0.12 (+1.32%)
At close · Aug 14
Market Cap
$986.47M
Shares
107.23M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$9.20
Open$9.09
Day$8.73–9.35
52W close$3.93–11.15
Avg vol 30d1.1M
Short int17.0M · 15.9% float · 16.2d
Short vol57%
Last earningsFeb 18, 2025
DataOct 2022–Aug 2026
Filing10-Q · Aug 6
Raw chart and full-history price indicators begin at the captured split on Oct 28, 2022; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+33%
above
Price vs 50-day avg
+6%
above
RSI (14)
58
neutral
MACD trend
Positive
52-week position
73%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+6%
trailing
6-month return
+57%
trailing
YTD return
+63%
this year
Relative strength
+43%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $9 › 200d $7 — 50d above 200d
Institutional flow
Accumulating
+3% holders QoQ · +37 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
15.89% of float · ▼ -3.6% MoM · 16.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
156 holders — near 3-yr high, broad support
Squeeze score
86
high risk · 0–100
Fundamentals
Revenue growth
−41%
Y/Y
EPS growth
+35%
Y/Y
Free cash flow
$-157.4M
Balance sheet
$59.9M
net cash
Quant / Vol
risk profile
Volatility
79%
annualized · 1-yr
Max drawdown
−39%
past year
ATR
5.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+33%
Bullish
Price vs 50-day avg
+6%
Bullish
RSI (14)
58
Neutral
MACD trend
Positive
Bullish
52-week position
73%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $9 › 200d $7 — 50d above 200d
Institutional flow
Accumulating
+3% holders QoQ · +37 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
15.89% of float · ▼ -3.6% MoM · 16.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
156 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4
Now $9 · 73%
Range high $11
vs 200-day avg +33%
vs 50-day avg +6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SLDB
this stock
Solid Biosciences Inc.
|
$986.47M | +63.1% | -40.6% | — | 15.9% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Oct 28, 2022; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SLDB | +9.7% | +5.5% | +56.7% | +14.1% | +63.1% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +9.3% | +1.1% | +43.0% | +10.2% | +49.3% |
Key facts
CIK
1707502
CUSIP
83422E204
13F (30d)
157 filings
150 filers
Visit website
Investor relations